Focused On-demand Library for Protein SERAC1

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We use our state-of-the-art dedicated workflow for designing focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

PARTNER
Receptor.AI
 
UPACC
Q96JX3

UPID:
SRAC1_HUMAN

ALTERNATIVE NAMES:
Serine active site-containing protein 1

ALTERNATIVE UPACC:
Q96JX3; Q49AT1; Q5VTX3; Q6PKF3

BACKGROUND:
The SERAC1 protein, known for its essential role in mitochondrial function and cholesterol distribution within cells, engages in the critical process of phosphatidylglycerol remodeling. It is believed to be involved in producing phosphatidylglycerol-36:1 through a specific biochemical pathway and plays a part in the biosynthesis of bis(monoacylglycerol)phosphate.

THERAPEUTIC SIGNIFICANCE:
Mutations affecting SERAC1 are associated with a severe autosomal recessive disorder characterized by a spectrum of symptoms including psychomotor development delays and sensorineural deafness. The exploration of SERAC1's function offers promising avenues for the development of targeted treatments for mitochondrial and lipid metabolism disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.


Page 1145 of 8789